Company Profile

Acenxion Biosystems Inc
Profile last edited on: 9/10/22      CAGE: 8JVH4      UEI: G82BLD378S63

Business Identifier: Enabling fast access to Phenotypic AST results
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

2002 West 39th Avenue Suite 1004
Kansas City, KS 66103
Location: Single
Congr. District: 03
County: Wyandotte

Public Profile

The scalable, automated AST system offered by Acenxion Biosystems is designed seamlessly to fit into current clinical workflows and to reduce time required for phenotypic AST results from days to just hours. This serves to allow clinicians rapid use of a targeted treatment thereby minimizing antibiotic exposure to AMR pressures.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2023 2 NIH $2,934,394
Project Title: An automated, scalable, and rapid AST system for Gonorrhea STIs

Key People / Management

  Roy R Swiger -- CEO

  Andrew Isakson -- Director of Product Development

  Sachidevi Puttaswamy -- Director of Systems Integration

  Brian Struchtemeyer

Company News

There are no news available.